Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 1.65B -3.2% |
| Revenue (ttm) | 66.41M +11.1% |
| Net Income | -559.78M |
| EPS | -1.17 |
| Shares Out | 530.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,129,150 |
| Open | 2.920 |
| Previous Close | 2.960 |
| Day's Range | 2.882 - 3.140 |
| 52-Week Range | 2.770 - 7.180 |
| Beta | 1.05 |
| Analysts | Hold |
| Price Target | 6.64 (+113.51%) |
| Earnings Date | May 6, 2026 |
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ... [Read more]
Financial Performance
In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RXRX stock is "Hold." The 12-month stock price target is $6.64, which is an increase of 113.51% from the latest price.
News
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.50 from $5 and keeps an Equal Weight rating on the shares.
Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing five clinical programs with near-term data, leveraging a unified AI-driven platform and proprietary data to improve drug discovery and trial efficiency. Strategic partnerships have generated over $500 million, while disciplined expense management supports a focus on high-impact programs.
Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)
Reports Q1 revenue $6.47B, consensus $15.78M. Cash, cash equivalents and restricted cash were $665.2M vs. $753.9M as of December 31, 2025. Continues to expect its cash runway to extend into…
Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026
AI-driven platform advances have led to clinical proof in multiple programs, strong partner inflows, and a 30% reduction in operating expenses. Cash runway extends into early 2028, with multiple clinical milestones and regulatory engagements expected in the next 12-18 months.
Recursion Pharmaceuticals Earnings release: Q1 2026
Recursion Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Recursion Pharmaceuticals Quarterly report: Q1 2026
Recursion Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
Recursion Pharmaceuticals Slides: Q1 2026
Recursion Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Recursion Reports First Quarter Financial Results and Provides Business Update
SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highligh...
Recursion Announces Board Transition
Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson...
Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan
JPMorgan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $11 and keeps an Overweight rating on the shares.
Recursion Pharmaceuticals Proxy statement: Proxy filing
Recursion Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Recursion Pharmaceuticals Proxy statement: Proxy filing
Recursion Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transitioned to a data-driven, diversified model post-merger, emphasizing regular clinical and partnership milestones. Major partnerships with Sanofi and Roche are progressing, with multiple clinical programs advancing and a strong focus on financial discipline and platform evolution.
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
Recursion Pharmaceuticals (RXRX) announced that Vicki Goodman will become Recursion’s chief medical officer effective April 6 as David Mauro transitions out of the role. Previously, she was executive ...
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodma...
Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
A unified AI-driven drug discovery platform has emerged from a recent merger, integrating chemistry, biology, and real-world data to optimize clinical development. The company has streamlined its pipeline, secured major partnerships, and achieved significant milestones, with multiple clinical readouts and operational efficiencies expected to drive near-term value.
Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a disciplined, data-driven approach to portfolio management, significant operational efficiencies, and robust partnership value realization. Strategic investments in proprietary data and AI integration, along with a focus on talent and organizational culture, underpin a strong competitive moat and financial flexibility.
PacBio appoints Gibson to Board of Directors
PacBio (PACB) announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (RXRX). Published...
Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The platform has evolved into an integrated, data-driven system with strong pharma and tech partnerships, enabling risk-diversified drug discovery and accelerated clinical progress. Financial discipline and strict go/no-go criteria guide pipeline advancement, with major data updates expected in 2024 and 2027.
Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA
BofA lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Neutral rating on the shares. The firm revised its estimates, updated operating expense…